Aims: The prostate cancer gene 3 (PCA3) is a prostate-specific, non-protein-coding RNA. It is overexpressed in prostate cancer compared with the normal prostate and has a negative expression in other tissues. This case-control study sought to analyze the frequency of the polymorphism PCA3 -845 G>A in participants without prostate cancer and patients with metastatic prostate cancer. Results: Carriers of GA and AA genotype had a higher risk for metastatic prostate cancer (odds ratio [OR] for genotype GA, 1.79 [95% confidence interval (CI), 1.14-2.29]; p=0.007; OR for genotype AA, 2.38 [95% CI, 1.22-4.65]; p=0.006). Furthermore, the recessive model showed that A allele carriers have an increased risk for developing metastatic prostate cancer (OR, 1.91 [95% CI, 1.26-2.90]; p=0.001). Conclusions: These results suggest a link between PCA3 and metastatic prostate cancer. The evaluation of individual genetic profiles, according to the PCA3 -845 G>A polymorphism, may elucidate the function of this gene and the mechanisms involved in its regulation and role in prostate cancer.
Get full access to this article
View all access options for this article.
References
1.
AlbertsB, JohnsonA, LewisJet al.2002. Molecular Biology of the Cell. Garland Science: New York.
2.
AubinSM, ReidJ, SarnoMJet al.2010. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol, 184:1947-1952.
3.
BussemakersMJ, van BokhovenA, VerhaeghGWet al.1999. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res, 59:5975-5979.
4.
CarrollSB. 2008. Evo-devo and an expanding evolutionary synthesis: a genetic theory of morphological evolution. Cell, 134:25-36.
5.
CondeL, VaquerizasJM, SantoyoJet al.2004. PupaSNP Finder: a web tool for finding SNPs with putative effect at transcriptional level. Nucleic Acids Res, 32:W242-248.
FerlayJ, AutierP, BoniolMet al.2007. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol, 18:581-592.
10.
FerlayJ, ParkinDM, Steliarova-FoucherE. 2010. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer, 46:765-781.
11.
GreenleeRT, MurrayT, BoldenS, WingoPA. 2000. Cancer statistics, 2000. CA Cancer J Clin, 50:7-33.
12.
HesselsD, SchalkenJA. 2009. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol, 6:255-261.
13.
HoulstonRS, WebbE, BroderickPet al.2008. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet, 40:1426-1435.
14.
JiaL, LandanG, PomerantzMet al.2009. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet, 5:e1000597.
15.
KleckaJ, HolubecL, PestaMet al.2010. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis. Anticancer Res, 30:665-670.
16.
MedeirosR, MoraisA, VasconcelosAet al.2002. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate, 53:88-94.
17.
MedeirosR, VasconcelosA, CostaSet al.2003. Steroid hormone genotypes ARStuI and ER325 are linked to the progression of human prostate cancer. Cancer Genet Cytogenet, 141:91-96.
18.
MedeirosRM, MoraisA, VasconcelosAet al.2002. Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin Cancer Res, 8:3433-3437.
19.
NakanishiH, GroskopfJ, FritscheHAet al.2008. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol, 179:1804-1809discussion 1809-1810.
20.
RibeiroR, VasconcelosA, CostaSet al.2004. Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate, 59:268-274.
21.
SalagierskiM, VerhaeghGW, JanninkSAet al.2010. Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. Prostate, 70:70-78.
22.
TeixeiraAL, RibeiroR, CardosoDet al.2008. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res, 14:3367-3371.
23.
TeixeiraAL, RibeiroR, MoraisAet al.2009. Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J, 9:341-346.
24.
van GilsMP, HesselsD, Hulsbergen-van de KaaCAet al.2008. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate, 68:1215-1222.
Vlaeminck-GuillemV, RuffionA, AndréJet al.2010. Urinary prostate cancer 3 test: toward the age of reason?Urology, 75:447-453.
27.
WhitmanEJ, GroskopfJ, AliAet al.2008. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol, 180:1975-1978discussion 1978-1979.
28.
YangJJ, ChengC, YangWet al.2009. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA, 301:393-403.
29.
ZhouW, ChenZ, HuWet al.2011. Association of short tandem repeat polymorphism in the promoter of prostate cancer antigen 3 gene with the risk of prostate cancer. PLoS One, 6:e20378.
